XML 55 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Agreements - Other Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2019
May 31, 2014
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2004
Significant Agreements              
Milestones and fees     $ 40,747,000 $ 37,630,000 $ 116,663,000 $ 105,125,000  
License agreement with Antibody Technology Company              
Significant Agreements              
Milestones and fees     100,000 100,000 600,000 2,100,000  
License agreement with Antibody Technology Company | Additional Research Fees              
Significant Agreements              
Collaborative arrangement amount paid and expensed   $ 300,000          
License Agreement With Fulcrum Therapeutics              
Significant Agreements              
Milestones and fees     600,000 0 1,700,000 0  
License Agreement With Fulcrum Therapeutics | Additional Research Fees              
Significant Agreements              
Collaborative arrangement amount paid and expensed $ 10,000,000.0            
License Agreement With Fulcrum Therapeutics | Additional Research Fees | Maximum              
Significant Agreements              
Total potential milestone payments (up to) 143,500,000            
License Agreement With Fulcrum Therapeutics | Research, Development and Commercial Milestone Payments | Maximum              
Significant Agreements              
Total potential milestone payments (up to) $ 295,000,000.0            
Non-collaborative Arrangement Transactions | Sotarcept | Development Milestone | Maximum              
Significant Agreements              
Total potential milestone payments (up to)             $ 2,000,000.0
Non-collaborative Arrangement Transactions | REBLOZYL Agreement | Development Milestone | Maximum              
Significant Agreements              
Total potential milestone payments (up to)             $ 700,000
Non-collaborative Arrangement Transactions | License Agreement with Non Profit Institution              
Significant Agreements              
Milestones and fees     $ 1,000,000.0 $ 0 $ 3,400,000 $ 1,600,000  
Non-collaborative Arrangement Transactions | License Agreement with Non Profit Institution | Minimum              
Significant Agreements              
Milestone fees payable as percentage of research and U.S. development progress and sublicensing revenue             10.00%
Royalty payable as percentage of net sales             1.00%
Non-collaborative Arrangement Transactions | License Agreement with Non Profit Institution | Maximum              
Significant Agreements              
Milestone fees payable as percentage of research and U.S. development progress and sublicensing revenue             25.00%
Royalty payable as percentage of net sales             3.50%